Patient-Preferences Favoring Treatment Discontinuation Are Reduced With Vedolizumab and Ustekinumab Compared With TNF Antagonists in Inflammatory Bowel Disease.
Anand KumarEmilie S KimPhilip KozanVinita JacobRandy S LongmanEllen J ScherlRobert J BattatDana J LukinPublished in: Crohn's & colitis 360 (2020)
Patient-preference favoring treatment discontinuation is improved with VDZ/UST compared with TNF-antagonist biologic therapy.